Latest Conference Coverage


Matthew Robbins, MD: Experience Adjusting to COVID-19 in Migraine Care

Matthew Robbins, MD: Experience Adjusting to COVID-19 in Migraine Care

June 18th 2020

The director of the Neurology Residency Program at Weill Cornell Medicine details his first-hand experience working in the epicenter of the COVID-19 pandemic and how his department adapted.


The Long-Term Impact of Addressing Gender Norms for Men With MS

The Long-Term Impact of Addressing Gender Norms for Men With MS

June 18th 2020

In Part 2 of this interview, Bryan Davis, PsyD, MS, clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS, details the impact that conversations about masculinity norms in MS can have on future trials and care.


Site Logo

Migraine History Pre-Concussion Linked to Worse Symptoms Post-Injury

June 18th 2020

Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.


Atogepant Proves Safe Without ALT Elevation in Healthy Participants

Atogepant Proves Safe Without ALT Elevation in Healthy Participants

June 18th 2020

Data presented at AHS 2020 suggest that 170-mg oral atogepant (Allergan) was both safe and well-tolerated, setting the stage the continued development in migraine prevention.


Celecoxib Oral Solution Offers Effective Alternative to Triptans in Acute Migraine

Celecoxib Oral Solution Offers Effective Alternative to Triptans in Acute Migraine

June 17th 2020

Data from a pair of phase 3 studies suggest that the recently approved celecoxib oral solution (Elyxyb; Dr. Reddy’s Laboratories) offers safe and effective acute treatment of episodic migraine.


Jessica Ailani, MD, FAHS: The Staying Power of Telemedicine in Headache

Jessica Ailani, MD, FAHS: The Staying Power of Telemedicine in Headache

June 17th 2020

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed how this year has proved that telemedicine is likely here to stay.


OnabotulinumtoxinA Proves Safe as Migraine Treatment for Pregnant Women

OnabotulinumtoxinA Proves Safe as Migraine Treatment for Pregnant Women

June 17th 2020

Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.


Migraine With Aura Linked to High Risk of Dementia in Later Life

Migraine With Aura Linked to High Risk of Dementia in Later Life

June 17th 2020

The results help to better understand the unique risk profiles of people with different subtypes of migraine.


Bryan Davis, PsyD, MS: Future Discussion on Masculinity Norms in MS

Bryan Davis, PsyD, MS: Future Discussion on Masculinity Norms in MS

June 16th 2020

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.


Youth With Migraine Improve Post-Preventive Treatment Regardless of Therapy Continuation

Youth With Migraine Improve Post-Preventive Treatment Regardless of Therapy Continuation

June 16th 2020

Results from the CHAMP trial of adolescents and children with migraine add to the already active and ongoing discussion surrounding the use of preventives in this population.


Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

June 16th 2020

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.


Combination OnabotulinumtoxinA and CGRP Treatment Safe and Successful in Migraine

Combination OnabotulinumtoxinA and CGRP Treatment Safe and Successful in Migraine

June 16th 2020

Further studies are needed to confirm the additional reductions in monthly headache days observed in patients with migraine who were treated with onabotulinumtoxinA and an add-on CGRP agent.


Ubrogepant Shows Efficacy for Patients With Chronic and Episodic Migraine

Ubrogepant Shows Efficacy for Patients With Chronic and Episodic Migraine

June 15th 2020

Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.


Jessica Ailani, MD: New Approvals and Nonpharmacologic Options for Headache

Jessica Ailani, MD: New Approvals and Nonpharmacologic Options for Headache

June 13th 2020

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital spoke to the specific datasets she is anticipating at the AHS 2020 meeting.


Why Learning About Masculine Norms Can Improve MS Care

Why Learning About Masculine Norms Can Improve MS Care

June 13th 2020

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.


AHS 2020: What to Expect From the Annual Scientific Meeting

AHS 2020: What to Expect From the Annual Scientific Meeting

June 12th 2020

Ahead of sessions kicking off on June 13, Jessica Ailani, MD, FAHS, offers a look into what data, plenary talks, and developments are set to be presented at the upcoming AHS 2020 annual meeting.


Bryan Davis, PsyD, MS: Behavioral Health and CMNI in Treating MS

Bryan Davis, PsyD, MS: Behavioral Health and CMNI in Treating MS

June 11th 2020

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.


Jessica Ailani, MD: The Ongoing Expansion in Headache Medicine

Jessica Ailani, MD: The Ongoing Expansion in Headache Medicine

June 11th 2020

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to the rapid expansion of headache medicine and what new research will be discussed at AHS 2020.


Jessica Ailani, MD: Plenary Talks at the AHS 2020 Annual Meeting

Jessica Ailani, MD: Plenary Talks at the AHS 2020 Annual Meeting

June 9th 2020

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed what topics the plenary talks will cover at AHS 2020.


Natalizumab Sets Itself Apart From Other MS Treatments

Natalizumab Sets Itself Apart From Other MS Treatments

June 9th 2020

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.


Jessica Ailani, MD: What to Expect From the American Headache Society Meeting

Jessica Ailani, MD: What to Expect From the American Headache Society Meeting

June 8th 2020

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to what to expect from this year’s annual scientific meeting.

© 2024 MJH Life Sciences

All rights reserved.